FDA’s approval of AstraZeneca PLC’s ovarian cancer drug Lynparza (olaparib) reflects the different prisms through which the agency views benefit/risk in the relapse and maintenance settings.
It also shows an agency – and particularly an oncology review division – willing to go the extra mile to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?